Cargando…

Bariatric Surgery: Targeting pancreatic β cells to treat type II diabetes

Pancreatic β-cell function impairment and insulin resistance are central to the development of obesity-related type 2 diabetes mellitus (T2DM). Bariatric surgery (BS) is a practical treatment approach to treat morbid obesity and achieve lasting T2DM remission. Traditionally, sustained postoperative...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Tiantong, Zou, Xi, Ruze, Rexiati, Xu, Qiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9975540/
https://www.ncbi.nlm.nih.gov/pubmed/36875493
http://dx.doi.org/10.3389/fendo.2023.1031610
_version_ 1784898893021970432
author Liu, Tiantong
Zou, Xi
Ruze, Rexiati
Xu, Qiang
author_facet Liu, Tiantong
Zou, Xi
Ruze, Rexiati
Xu, Qiang
author_sort Liu, Tiantong
collection PubMed
description Pancreatic β-cell function impairment and insulin resistance are central to the development of obesity-related type 2 diabetes mellitus (T2DM). Bariatric surgery (BS) is a practical treatment approach to treat morbid obesity and achieve lasting T2DM remission. Traditionally, sustained postoperative glycemic control was considered a direct result of decreased nutrient intake and weight loss. However, mounting evidence in recent years implicated a weight-independent mechanism that involves pancreatic islet reconstruction and improved β-cell function. In this article, we summarize the role of β-cell in the pathogenesis of T2DM, review recent research progress focusing on the impact of Roux-en-Y gastric bypass (RYGB) and vertical sleeve gastrectomy (VSG) on pancreatic β-cell pathophysiology, and finally discuss therapeutics that have the potential to assist in the treatment effect of surgery and prevent T2D relapse.
format Online
Article
Text
id pubmed-9975540
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-99755402023-03-02 Bariatric Surgery: Targeting pancreatic β cells to treat type II diabetes Liu, Tiantong Zou, Xi Ruze, Rexiati Xu, Qiang Front Endocrinol (Lausanne) Endocrinology Pancreatic β-cell function impairment and insulin resistance are central to the development of obesity-related type 2 diabetes mellitus (T2DM). Bariatric surgery (BS) is a practical treatment approach to treat morbid obesity and achieve lasting T2DM remission. Traditionally, sustained postoperative glycemic control was considered a direct result of decreased nutrient intake and weight loss. However, mounting evidence in recent years implicated a weight-independent mechanism that involves pancreatic islet reconstruction and improved β-cell function. In this article, we summarize the role of β-cell in the pathogenesis of T2DM, review recent research progress focusing on the impact of Roux-en-Y gastric bypass (RYGB) and vertical sleeve gastrectomy (VSG) on pancreatic β-cell pathophysiology, and finally discuss therapeutics that have the potential to assist in the treatment effect of surgery and prevent T2D relapse. Frontiers Media S.A. 2023-02-15 /pmc/articles/PMC9975540/ /pubmed/36875493 http://dx.doi.org/10.3389/fendo.2023.1031610 Text en Copyright © 2023 Liu, Zou, Ruze and Xu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Endocrinology
Liu, Tiantong
Zou, Xi
Ruze, Rexiati
Xu, Qiang
Bariatric Surgery: Targeting pancreatic β cells to treat type II diabetes
title Bariatric Surgery: Targeting pancreatic β cells to treat type II diabetes
title_full Bariatric Surgery: Targeting pancreatic β cells to treat type II diabetes
title_fullStr Bariatric Surgery: Targeting pancreatic β cells to treat type II diabetes
title_full_unstemmed Bariatric Surgery: Targeting pancreatic β cells to treat type II diabetes
title_short Bariatric Surgery: Targeting pancreatic β cells to treat type II diabetes
title_sort bariatric surgery: targeting pancreatic β cells to treat type ii diabetes
topic Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9975540/
https://www.ncbi.nlm.nih.gov/pubmed/36875493
http://dx.doi.org/10.3389/fendo.2023.1031610
work_keys_str_mv AT liutiantong bariatricsurgerytargetingpancreaticbcellstotreattypeiidiabetes
AT zouxi bariatricsurgerytargetingpancreaticbcellstotreattypeiidiabetes
AT ruzerexiati bariatricsurgerytargetingpancreaticbcellstotreattypeiidiabetes
AT xuqiang bariatricsurgerytargetingpancreaticbcellstotreattypeiidiabetes